AI eyes hidden heart condition: could algorithms catch what doctors miss?
NCT ID NCT07062848
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This study is testing whether artificial intelligence can detect transthyretin amyloid cardiomyopathy (ATTR-CM), a serious and often underdiagnosed heart condition, earlier than usual. Researchers will use AI algorithms to analyze routine ECGs and heart ultrasounds from up to 1.5 million people aged 50 to 95 across diverse US health systems. The goal is to see how common the condition really is and whether the AI tools can reliably flag it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an artificial intelligence toolkit that analyzes ECGs and ultrasounds to detect signs of transthyretin amyloid cardiomyopathy
- What this could lead to
- If successful, this AI approach could enable earlier, faster detection of a underdiagnosed heart condition, potentially improving outcomes for thousands of patients.
- What could go wrong
- This is an observational study, not a treatment trial. The AI algorithms may not perform equally well across all populations or healthcare settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN (TTR) AMYLOID CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henry Ford Health
Detroit, Michigan, 48202, United States
-
Houstin Methodist
Houston, Texas, 77030, United States
-
Medical University of South Carolina (MUSC) Health
Charleston, South Carolina, 29425, United States
-
Montefiore
The Bronx, New York, 10467, United States
-
Mount Sinai
New York, New York, 10029, United States
-
Providence Health
Tigard, Oregon, 97224, United States
-
The University of Chicago
Chicago, Illinois, 60637, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
-
University of California - San Francisco (UCSF) Health
San Francisco, California, 94143, United States
-
University of Virginia School of Medicine
Charlottesville, Virginia, 22903, United States
-
University of Washington Medicine
Seattle, Washington, 98195, United States
-
Yale New Haven Health System
New Haven, Connecticut, 06519, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.